Effect of Ginkgo Biloba Extract on Cognitive Function in Acute Ischemic Stroke

Inclusion Criteria: 1. Patients with a definitive clinical diagnosis of acute ischemic stroke; 2. Age≥18 years, regardless of sex； 3. Primary education level or higher; baseline MoCA score of 10-25 points; 4. Able to complete cognitive scale scoring; 5. Informed consent is signed and ginkgo biloba extract therapy is initiated within 14 days of onset. Exclusion Criteria: 1. Transient ischemic attack； 2. Patients who received emergency reperfusion therapy (including intravenous thrombolysis and endovascular thrombectomy) at onset; 3. Combined with other neurological diseases, such as neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Lewy body dementia, and frontotemporal dementia), optic neuritis, epilepsy, central nervous system infections (e.g., AIDS and syphilis), traumatic brain injury dementia, etc； 4. Currently using psychoactive medications (e.g., antidepressants) or anti-epileptic drugs, or if the time since their last use of these medications was less than 5 half-lives (per the pharmacokinetics of each specific medication; for drugs with unknown half-lives, a 1 month washout period was required)； 5. Had a pre-existing diagnosis of a cognitive disorder； 6. Currently taking medications intended to improve cognitive function or prevent dementia (e.g., cholinesterase inhibitors, memantine, nootropics), or if the washout period since their last use of these medications was less than 5 half-lives as specified in each drug's pharmacokinetics. For drugs with unknown half-lives, a minimum 1 month washout period was required； 7. Severe liver and kidney dysfunction; 8. Active ulcer or bleeding diathesis； 9. Allergy to preparations containing ginkgo biloba extract； 10. Pregnant or lactating women, patients with a life expectancy less than 6 months, and those unable to complete the study for other reason； 11. Unwillingness to be followed up or poor treatment compliance; 12. Those who are participating in other clinical investigators, or who have participated in other clinical studies within 3 months prior to enrollment; 13. Other conditions that the investigators deemed unsuitable for enrollment.